Suresh Sureddi, MD
Psychiatry · Plano, TXNPI 1710932561
Payments from drug & device makers
Across 2,937 payments — averaging $1996.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2.3M
- E.r. Squibb & Sons, L.L.C.$914K
- Alkermes, Inc.$562K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$505K
- Otsuka America Pharmaceutical, Inc.$339K
- Neurocrine Biosciences, Inc.$332K
- plus $953K from 18 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 369 | $2,257,926 |
| E.r. Squibb & Sons, L.L.C. | 53 | $914,455 |
| Alkermes, Inc. | 747 | $562,272 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 30 | $505,450 |
| Otsuka America Pharmaceutical, Inc. | 454 | $338,881 |
| Neurocrine Biosciences, Inc. | 321 | $331,583 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 288 | $291,460 |
| Axsome Therapeutics, Inc. | 243 | $250,282 |
| AbbVie(2 entities) | 232 | $191,463 |
| Boehringer Ingelheim | 10 | $152,152 |
| Sage Therapeutics, LLC | 6 | $27,130 |
| Boehringer Ingelheim RCV GmbH & Co KG | 17 | $11,805 |
| Janssen Research & Development, LLC | 11 | $8,265 |
| Sunovion Pharmaceuticals Inc. | 74 | $7,977 |
| H. Lundbeck A S | 3 | $7,010 |
| Johnson & Johnson(2 entities) | 44 | $3,942 |
| Vanda Pharmaceuticals Inc. | 6 | $806 |
| Jazz Pharmaceuticals Inc. | 5 | $267 |
| Tris Pharma Inc | 14 | $156 |
| Harmony Biosciences LLC | 3 | $90 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Indivior Inc. | 2 | $38 |
| Lundbeck LLC | 2 | $35 |
| Evofem Biosciences, Inc. | 1 | $17 |
How this compares
$5,863,502 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Plano
- Sejal MehtaPlano$3.3M
- David CrumpackerPlano$386K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Marshall LucasThe Woodlands$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.